Krebs Biochemicals & Industries Limited (BOM:524518)
India
· Delayed Price · Currency is INR 75.85
+2.85 (3.90%)
At close: May 7, 2025
BOM:524518 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 491.84 | 504.22 | 521.34 | 597.03 | 386.06 | 235.84 | Upgrade
|
| Other Revenue | - | - | - | - | 140.77 | 88.11 | Upgrade
|
| Revenue | 491.84 | 504.22 | 521.34 | 597.03 | 526.84 | 323.95 | Upgrade
|
| Revenue Growth (YoY) | -1.45% | -3.29% | -12.68% | 13.32% | 62.63% | -30.69% | Upgrade
|
| Cost of Revenue | 106.91 | 93.99 | 277.16 | 441.18 | 515.96 | 323 | Upgrade
|
| Gross Profit | 384.93 | 410.23 | 244.19 | 155.85 | 10.87 | 0.95 | Upgrade
|
| Selling, General & Admin | 176 | 170.53 | 165.32 | 159.81 | 167.75 | 159.75 | Upgrade
|
| Other Operating Expenses | 332.04 | 323.98 | 231.74 | 328.01 | 12.6 | 25.77 | Upgrade
|
| Operating Expenses | 575.96 | 562.17 | 462.65 | 550.79 | 232.39 | 232.31 | Upgrade
|
| Operating Income | -191.02 | -151.95 | -218.46 | -394.94 | -221.52 | -231.36 | Upgrade
|
| Interest Expense | -55.68 | -46.86 | -29.71 | -53.85 | -62.72 | -59.99 | Upgrade
|
| Interest & Investment Income | 1.56 | 1.56 | 1.27 | 3.58 | 0.72 | 2.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.04 | -0.02 | -0.06 | -0.07 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -245.18 | -197.28 | -246.92 | -445.27 | -283.59 | -288.79 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.07 | Upgrade
|
| Pretax Income | -245.18 | -197.28 | -246.92 | -445.27 | -283.59 | -288.72 | Upgrade
|
| Net Income | -245.18 | -197.28 | -246.92 | -445.27 | -283.59 | -288.72 | Upgrade
|
| Net Income to Common | -245.18 | -197.28 | -246.92 | -445.27 | -283.59 | -288.72 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 22 | 22 | 22 | 20 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 22 | 22 | 22 | 20 | 18 | Upgrade
|
| Shares Change (YoY) | 0.07% | - | - | 9.89% | 9.00% | 8.24% | Upgrade
|
| EPS (Basic) | -11.37 | -9.15 | -11.45 | -20.65 | -14.45 | -16.04 | Upgrade
|
| EPS (Diluted) | -11.37 | -9.15 | -11.45 | -20.65 | -14.45 | -16.04 | Upgrade
|
| Free Cash Flow | - | -71.11 | -398.71 | -442.95 | -400.81 | -449.09 | Upgrade
|
| Free Cash Flow Per Share | - | -3.30 | -18.49 | -20.54 | -20.43 | -24.95 | Upgrade
|
| Gross Margin | 78.26% | 81.36% | 46.84% | 26.11% | 2.06% | 0.29% | Upgrade
|
| Operating Margin | -38.84% | -30.14% | -41.90% | -66.15% | -42.05% | -71.42% | Upgrade
|
| Profit Margin | -49.85% | -39.13% | -47.36% | -74.58% | -53.83% | -89.12% | Upgrade
|
| Free Cash Flow Margin | - | -14.10% | -76.48% | -74.19% | -76.08% | -138.63% | Upgrade
|
| EBITDA | -123.64 | -86.12 | -154.71 | -338.36 | -172.88 | -187.17 | Upgrade
|
| EBITDA Margin | -25.14% | -17.08% | -29.68% | -56.67% | -32.81% | -57.78% | Upgrade
|
| D&A For EBITDA | 67.38 | 65.83 | 63.75 | 56.58 | 48.64 | 44.19 | Upgrade
|
| EBIT | -191.02 | -151.95 | -218.46 | -394.94 | -221.52 | -231.36 | Upgrade
|
| EBIT Margin | -38.84% | -30.14% | -41.90% | -66.15% | -42.05% | -71.42% | Upgrade
|
| Revenue as Reported | 497.65 | 508.73 | 527.55 | 608.59 | 543.22 | 337.77 | Upgrade
|
| Advertising Expenses | - | - | - | - | 0.05 | 0.98 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.